Media coverage about Hill-Rom (NYSE:HRC) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hill-Rom earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 45.6818393335863 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern’s analysis:
- Hill-Rom’s (HRC) Buy Rating Reaffirmed at Barclays (americanbankingnews.com)
- Hill-Rom (HRC) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Hill-Rom Holdings (HRC) Prelim. Q1 Revenue Tops Views (streetinsider.com)
- Hill-Rom Announces Preliminary Fiscal First Quarter Financial Results And Comments On Expected Impact Of New U.S. Tax Reform Legislation (finance.yahoo.com)
- Hill-Rom (HRC) Updates Q1 Earnings Guidance (americanbankingnews.com)
Several research firms recently commented on HRC. Barclays reiterated a “buy” rating and set a $100.00 target price on shares of Hill-Rom in a research report on Wednesday. Zacks Investment Research downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price on the stock in a research report on Wednesday, January 3rd. Morgan Stanley downgraded shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Finally, KeyCorp reiterated a “buy” rating and set a $94.00 target price on shares of Hill-Rom in a research report on Thursday, December 21st. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Hill-Rom presently has a consensus rating of “Hold” and an average price target of $93.00.
Shares of Hill-Rom (NYSE:HRC) traded down $0.17 during midday trading on Friday, hitting $86.79. 693,352 shares of the stock were exchanged, compared to its average volume of 478,989. The firm has a market cap of $5,720.00, a P/E ratio of 43.61, a P/E/G ratio of 1.65 and a beta of 1.19. Hill-Rom has a 1 year low of $57.18 and a 1 year high of $88.91. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. The firm had revenue of $738.30 million for the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 9.36% and a return on equity of 21.07%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.18 EPS. sell-side analysts expect that Hill-Rom will post 4.32 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 15th were given a $0.18 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.83%. Hill-Rom’s dividend payout ratio (DPR) is currently 36.18%.
In related news, CEO John J. Greisch sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares in the company, valued at approximately $19,119,079.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total transaction of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at approximately $88,467.34. The disclosure for this sale can be found here. Insiders sold a total of 226,241 shares of company stock worth $18,708,644 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.